Introduction
============

Endometrial carcinoma, the fourth most prevalent gynecologic malignancy, is a disease driven predominantly by the neoplastic proliferation of endometrial epithelial cells.[@b1-ott-9-7019] The high-risk group suffering from endometrial carcinoma is postmenopausal women, with up to 86% of patients aged \>50 years.[@b2-ott-9-7019] At present, although the etiology has not been completely clear, this disease may be attributed to the changes in endogenous and exogenous hormones that lead to the unopposed estrogen hypothesis. Namely, exposure of the endometrium to high levels of estrogen and low progesterone contributes to the development of endometrial cell and further enhances the risk of cancer.[@b1-ott-9-7019] Interestingly, operation is the principal way for patients with endometrial carcinoma, such as hysterectomy and bilateral salpingo-oophorectomy, followed by other auxiliary treatments.[@b3-ott-9-7019] In recent years, along with the improvement in molecular biological fields, it has been found that DNA repair polymorphism participates in the development of tumors, such as base excision repair (BER) and nucleotide excision repair (NER).[@b4-ott-9-7019] The polymorphism of certain repair pathway can affect DNA repair capacity, and thereby influence risk rate of cancer as well as therapeutic efficacy.[@b5-ott-9-7019]

*XRCC1* is an important DNA repair gene and plays a critical role in the process of BER.[@b6-ott-9-7019] Located on chromosome 19q13.2-13.3, 33 kb-long *XRCC1* embraces 17 exons and encodes a 70 kDa protein.[@b7-ott-9-7019] The mutation of the 399 Gln allele located on the *XRCC1* rs25487 greatly affects the BER function, which is closely associated with a higher incidence of lung cancer.[@b8-ott-9-7019] *ERCC1* is believed to be an essential polypeptide of the NER system, which promotes the repairing of damaged DNA through removal of the DNA--platinum adduct that inhibits DNA synthesis in cancer cells.[@b9-ott-9-7019] A previous study showed that *ERCC1* C118T synonymous single nucleotide polymorphism (SNP; No rs11615) affected the ERCC1 mRNA and protein expression levels that in return influence sensitivity to platinum-based chemotherapy in lung cancer.[@b10-ott-9-7019] *XPA* functions to assist DNA excision repair to maintain genomic integrity by identifying damage position as well as interacting with many core repair factors.[@b11-ott-9-7019] *XPA* A23G polymorphism, also known as *XPA* (-4) G-to-A polymorphism (rs1800975), is associated with the response to DNA damage and high risk of non-small-cell lung cancer and gastric cancer.[@b12-ott-9-7019],[@b13-ott-9-7019] Up to now, less attention has been paid to the relationship between DNA damage gene polymorphism and endometrial carcinoma. Given this, the purpose of this study is to assess the prognostic value of *ERCC1/XRCC1/XPA* gene polymorphisms in patients with endometrial adenocarcinoma undergoing two cycles of chemotherapy. This study will not only help to understand the mechanism of this disease but also help to facilitate the prevention of this tumor.

Patients and methods
====================

Patients
--------

From January 2010 to December 2012, a total of 108 patients with endometrial carcinoma undergoing operative treatments in The 2nd Affiliated Hospital, Harbin Medical University, were enrolled into a case group with a mean age of 52.91±7.35 years (range: 35--65). The surgical cases were divided into stages according to the standards of Federation of Gynecology and Obstetrics (FIGO),[@b14-ott-9-7019] including 44 cases in I stage, 18 cases in II stage, 46 cases in III stage, and zero case in IV stage. And there were 88 (81.5%) cases with endometrioid carcinoma and 20 (18.5%) cases with nonendometrioid carcinoma. All patients underwent extrafascial hysterectomy with bilateral adnexectomy and pelvic cavity abdominal aorta lymph node dissection. Also, all patients with complete clinical data neither accept any treatment before hospital admission nor suffer from other malignant tumors. They had no mental disorder and unconscious disorders, blood coagulation dysfunction, severe cardiac, cerebral vessels disease, and liver and kidney dysfunction. Meanwhile, the patients did not accept other antineoplastic treatments before treatment with cisplatin plus fluorouracil. The specific dosages of chemotherapeutics were cisplatin (75 mg/m^2^) VD d1 and fluorouracil (500 mg/m^2^). Therapeutic evaluations of the patients who were administered with 5 mg granisetron as antiemesis and 15 mg furosemidum intravenously (3--4 weeks as a cycle) were performed after 2 weeks in accordance with the principles of response evaluation criteria in solid tumors (RECIST). Another 110 cases confirmed by physical examination in the corresponding period were randomly collected as a control group with a mean age of 50.00±8.52 years (ra1). All patients and their families knew the study plan and have signed the written informed consents. Also, this study (NCT: ChiCTR-RRC-16009412) was approved by the ethics committee of The 2nd Affiliated Hospital, Harbin Medical University.

DNA extraction
--------------

Before chemotherapy, from two group of patients, 3 mL of venous blood was collected in a tube containing sodium citrate, which is an anticoagulant. Each tube was labeled with the number and name of the subject. After 10 minutes of centrifugation (3,000 rpm), the DNA kit (Takara, Japan) was applied to draw the whole blood DNA in peripheral blood, and the DNA concentration detector (NANODROP2000; Thermo Fischer Scientific, Waltham, MA, USA) was employed to detect the purity of DNA and the concentration of DNA at an optical density (OD) of 260 nm and 280 nm. The mean concentration was detected as 100±20 ng/L and the DNA purity was determined in 1.6--1.8 according to the ratio of A260 nm/A280 nm. The extracted DNA was stored at −40°C for further use.

Detections of single nucleotide polymorphisms
---------------------------------------------

The primer was purchased from Nanjing Lejin Biotech Co., Ltd. (Nanjing, People's Republic of China) ([Table 1](#t1-ott-9-7019){ref-type="table"}). A polymerase chain reaction (PCR) kit was bought from Vazyme Biotech Co., Ltd. (Nanjing, People's Republic of China), with 20 mL general reaction system containing 1 mL of extracted DNA, 1 mL of upstream and 1 mL of downstream primers (10 pmol/mL), 10 mL of PCR mixture and 7 mL of deionized water. The reaction conditions include: predenaturation at 95°C for 5 minutes, then with a total of 40 circulations of denaturation at 95°C for 30 seconds, annealing at 65°C for 40 seconds, extension at 72°C for 7 minutes and final extension at 72°C for 10 minutes. After 3.5% agarose gel electrophoresis (containing 0.5 mg/mL ethidium bromide), 4 mL amplification products and 1 mL bromophenol blue sample buffer solution were mixed with each other, and then the sample was added. The amplification bands were observed and photographed when the mixture was subject to 0.5× Tris--boric acid--EDTA buffer solution and 70 V electrophoresis for 15 minutes under an ultraviolet lamp to test whether PCR was successful. The products of *ERCC1* rs11615*/XRCC1* rs25487*/XPA* rs1800975 underwent enzyme digestion of BsrDI (37°C), MspI (37°C), and cleavage SfcI (37°C), which were purchased from New England Biolabs, Ipswich, MA, USA, and the operation procedures were carried out according to the instructions. The enzyme-digested products were separated in 3.5% agarose gel electrophoresis at 120 V for 40 minutes, and the band was observed in an ultraviolet lamp. The sample (10%) was sequenced bidirectionally (Sangon Biotech Co., Ltd., Shanghai, China) to test the results of PCR--restriction fragment length polymorphism.

Efficacy evaluation
-------------------

The patients were reexamined according to the evaluation standards of RECIST[@b15-ott-9-7019] after two-cycle chemotherapy. Complete remission (CR) meant that the whole measureable diseases have completely disappeared for 4 weeks; partial response (PR) meant that the maximum diameter of the lesions reduced \<30% and maintained for \<4 weeks; no-change (NC) was between PR and progressive disease (PD) and PD meant that the maximum diameter overtopped 20% or new lesions appear. Patients with CR and PR belong to efficient chemotherapy cases, while patients with stable disease and PD belong to inefficient ones.

Evaluation of toxic effects
---------------------------

Relapses in patients were recorded during follow-up after chemotherapy, and chemotherapy toxic reaction of the patients was defined according to the evaluation standards of toxic reaction recommended by the World Health Organization.[@b16-ott-9-7019] The grading standards of nausea and vomiting were as follows: 0, no nausea and vomiting symptoms; I, vomiting less than two times every day, which did not affect daily life; II, vomiting less than or equivalent to five times, which slightly affected daily life, and III--IV, vomiting more than five times, which was addressed by remaining in bed and taking medicine according to indications.

Follow-up
---------

A total of 108 patients with endometrial carcinoma were followed up, with the follow-up rate reaching 93.5%. It ended because of death or censoring time with a follow-up of 1--3 years (mean follow-up of 2.5 years). The patients were followed up by telephone, petition, and outpatient review to understand the postoperative survivals and recovery status of patients, for example, whether the patients relapsed or survived. If relapsed, what were the sites and treatments? If died, what were the specific causes and time of death?

Statistical analysis
--------------------

The SPSS 20.0 integrated software (SPSS Inc., Chicago, IL, USA) was employed for data analysis. Measurement data were exhibited as mean ± SD; independent-sample *t*-test was used for comparison between two groups, and analysis of variance was used for comparison among more than two groups. Welch was used when measurement data failed to satisfy homogeneity of variance. Least significant difference was applied to compare homogeneity of variance among groups. Tamhane's T2 test was used for multiple comparisons between groups. Pearson chi-square test was employed to compare the frequency distribution of genotype and allele among groups. Logistic regression analysis was used to confirm the relationships between *ERCC1/XRCC1/XPA* gene polymorphisms and the postoperative chemotherapy efficacy of endometrial carcinoma. Hardy--Weinberg balance was tested by chi-square test, and Kaplan--Meier was performed in survival analysis. The Cox risk ratio model was adopted in multiplicity. Moreover, *P* was bilaterally inspected and *P*\<0.05 indicated statistically significant.

Results
=======

Clinical characteristics of subjects
------------------------------------

No significant difference was found between the case group and control group concerning the age, body mass index (BMI), and menopause (all *P*\>0.05). Among the 108 patients with endometrial carcinoma, 88 presented with endometrioid carcinoma and 20 presented with nonendometrioid carcinoma. Furthermore, 53 patients presented no muscular invasion or \<1/2 invasion, while 55 exhibited over 1/2 muscular invasion. The maximum lesion diameter was \<1 cm in 29 patients, between 1 cm and 2 cm in 45 patients and \>2 cm in 34 patients.

Frequency distribution of *ERCC1/XRCC1/XPA* gene polymorphisms
--------------------------------------------------------------

Allele frequency examined by Hardy--Weinberg equilibrium was tested by chi-square test. The Hardy--Weinberg equilibrium test showed that the allele frequency of *ERCC1* rs11615/*XRCC1* rs25487/*XPA* rs1800975 in the control group was in balance (*P*\>0.05), signaling a strong group representation.

The electropherogram of *ERCC1* rs11615 is displayed in [Figure 1A](#f1-ott-9-7019){ref-type="fig"}. There was a statistical difference regarding genotype and allele frequency between the case group and the control group (all *P*\<0.05, [Table 2](#t2-ott-9-7019){ref-type="table"}), which implied that *ERCC1* rs11615 polymorphism might be associated with the risk of endometrial carcinoma. Compared with the patients with GG in *ERCC1* rs11615, the patients with AA + GA had an increased risk of endometrial carcinoma (GA vs GG, OR =3.964, 95% CI =2.013--7.805, *P*\<0.05; AA vs GG, OR =6.098, 95% CI =1.252--29.700, *P*\<0.05; AA + GA vs GG, OR =4.215, 95% CI =2.218--8.010, *P*\<0.05).

The electropherogram of *XRCC1* rs25487 is outlined in [Figure 1B](#f1-ott-9-7019){ref-type="fig"}. There were significant differences regarding genotype and allele frequency between the case group and control group (all *P*\<0.05), which implied that *XRCC1* rs25487 polymorphism might be lined with the risk of endometrial carcinoma. Compared with the patients with GG in *XRCC1* rs25487, the patients with AA + GA had an increased risk of endometrial carcinoma (GA vs GG, OR =1.806, 95% CI =1.014--3.215, *P*\<0.05; AA vs GG, OR =2.512, 95% CI =1.021--6.178, *P*\<0.05; AA + GA vs GG, OR =1.947, 95% CI =1.136--3.336, *P*\<0.05; A vs G, OR =1.738, 95% CI =1.148--2.629, *P*\<0.05). Therefore, AA + GA genotype of *XRCC1* was a risk factor for endometrial carcinoma.

The electropherogram of *XPA* rs1800975 is illustrated in [Figure 1C](#f1-ott-9-7019){ref-type="fig"}. No significant difference was found regarding genotype and allele frequency between the case group and control group (all *P*\>0.05).

Correlations of *ERCC1/XRCC1/XPA* gene polymorphisms with clinical characteristics
----------------------------------------------------------------------------------

After the stratified analysis of the age, BMI, and pathologic type of the 108 patients, no significant difference was revealed between the AA + GA frequency and GG frequency of *ERCC1* rs11615/*XRCC1* rs25487, and there was also no difference between the GG + GA frequency and AA frequency of *XPA* rs1800975 (all *P*\>0.05, [Table 3](#t3-ott-9-7019){ref-type="table"}). When the stratified analysis was made based on menopause, muscular invasion, maximum lesion diameter, tumor stage and lymphatic metastasis, the AA + GA frequency and GG frequency of *ERCC1* rs11615/*XRCC1* rs25487 were significantly different (all *P*\<0.05), while the the GG + GA frequency and AA frequency of *XPA* rs1800975 were not significant different (*P*\>0.05).

Correlations of *ERCC1/XRCC1/XPA* gene polymorphisms with chemotherapy efficacy
-------------------------------------------------------------------------------

Among the total 108 cases, 53 cases had clinical response to chemotherapy, achieving 49.1% of effective rate. The statistical data are listed in [Table 4](#t4-ott-9-7019){ref-type="table"}.

The effective rate of GA + AA in *ERCC1* rs11615 attained 36.2%, significantly lower than 59% of GG (*P*\<0.05), signifying that GG was more sensitive to chemotherapeutic drugs.

Moreover, in *XRCC1* rs25487, GA + AA reached the effective rate of 33.9%, lower than 69.6% of GG (*P*\<0.05), the latter of which demonstrated a more sensitivity to chemotherapy.

The AA and GA + GG in *XPA* gene exhibited 44.8% and 56.1% effective rate, respectively. There was no significant difference among the three groups (all *P*\>0.05).

Correlations of *ERCC1/XRCC1/XPA* gene polymorphisms with toxic effects
-----------------------------------------------------------------------

In both *ERCC1* rs11615 and *XRCC1* rs25487, compared with the patients with GG genotype, the digestive system and hematological system of patients with GA + AA genotype showed no significant difference in toxic effects (*P*\>0.05), while there were significant differences between the two genotypes concerning toxic effects in liver, kidney, and nervous system (both *P*\<0.05). The toxic effects of patients with GA + GG and AA in *XPA* rs1800975 demonstrated no statistical difference (all *P*\>0.05, [Table 5](#t5-ott-9-7019){ref-type="table"}).

Survival analysis
-----------------

The follow-up for endometrial carcinoma patients spanned for 1--3 years with a mean of 2.5 years. The overall survival rates of 1, 2, and 3 years after the surgery were 93.5%, 78.7%, and 70.4%, respectively. In *ERCC1* rs11615, among the patients with GG genotype, ten cases (16.4%) died and six cases lost contact, while among the patients with GA + AA, 22 cases (46.8%) died and five cases lost contact (all *P*\<0.05, [Figure 2A](#f2-ott-9-7019){ref-type="fig"}). In *XRCC1* rs25487, among the patients with GG genotype, three cases (6.5%) died and seven cases lost contact, while among the patients with GA + AA, 29 cases (46.8%) died and four cases lost contact (all *P*\<0.05, [Figure 2B](#f2-ott-9-7019){ref-type="fig"}). In *XPA* rs1800975, among the patients with AA genotype, 14 cases (34.1%) died and four cases lost contact, while among the patients with GA + AA, 18 cases (26.9%) died and seven cases lost contact (all *P*\>0.05, [Figure 2C](#f2-ott-9-7019){ref-type="fig"}).

The Cox regression analysis in [Table 6](#t6-ott-9-7019){ref-type="table"} revealed that the tumor stage and genes of *ERCC1* rs11615 and *XRCC1* rs25487 were independent risk factors of the prognosis of endometrial carcinoma (all *P*\<0.05). Specifically, the GG genotype in *ERCC1* rs11615 and *XRCC1* rs25487, and I + II stages were protective factors of the prognosis of endometrial carcinoma, while muscular invasion failed to be correlated with the prognosis of endometrial carcinoma.

Discussion
==========

In recent years, endometrial carcinoma is a growing global concern with important public health implications on women. Besides, the prevalence of endometrial carcinoma is tending to increase due to a long-term, excessive estrogen exposure without the protection of progesterone and poor postoperative treatment. Existing evidence shows that genetic characteristics may contribute to the development of endometrial carcinoma. More importantly, the DNA repair gene genetic polymorphisms are significantly involved with the risk of cancer occurrence.[@b17-ott-9-7019] Therefore, the study is designed to investigate the significance of DNA repair gene genetic polymorphisms (*XRCC1*, *ERCC1*, and *XPA*) on the risk occurrence of endometrial carcinoma and evaluation of chemotherapy efficacy in order to provide a theoretical basis for the prevention and treatment of the disease.

Initially, our findings revealed that gene polymorphism of *XRCC1* rs25487 was a risk factor for endometrial carcinoma. Namely, the patients with AA + GA had an increased risk of endometrial carcinoma when compared with the patients carrying GG genotype at *XRCC1* rs25487. To the best of our knowledge, XRCC1 plays an essential role in the BER pathway and functions as a scaffold protein, which bonds with DNA repair complex. *XRCC1* gene was identified by its function to restore the DNA repair capacity in the Chinese hamster ovary mutant cell line EM9 and to interact with poly(ADP-ribose) polymerase and DNA ligase III for recognizing and rejoining DNA strand breaks, as well as with DNA polymerase β and apurinic/apyrimidinic endonuclease I.[@b18-ott-9-7019]--[@b22-ott-9-7019] The most extensively studied SNPs of *XRCC1* gene are Arg399Gln (G\>A, rs25487) and Arg194Trp (C\>T, rs1799782), which have been reported to be associated with an altered DNA repair activity. At the same time, BER pathway is the main DNA repair pathway, which removes oxidized and alkylated bases. Various enzymes, including OGG1, XRCC1, and PARP1, participate in BER, which contribute to polymorphisms related to the risk of cancer.[@b8-ott-9-7019] A functional SNP in *XRCC1* rs25487 with a G to A base alteration results in an arginine to glutamine substitution. A study reported by Duell et al[@b23-ott-9-7019] discovered that the minor allele (A) for *XRCC1* rs25487, the 399Gln allele, was connected to an increased frequency of glycophorin mutation, enhanced DNA adduct levels, higher frequency of baseline sister chromatid exchange, as well as increased sensitivity to ionizing radiation, all of which might emerge due to weakened BER function. Therefore, our study speculated that the mutation GA of *XRCC1* rs25487 can cause the alteration of amino acid Arg-Gln, which is located in 399th codon, resulting in an increased risk of endometrial carcinoma by reducing the binding ability of XRCC1, PARP, DNA polymerase β, and ligase III.

Meanwhile, continuous analysis was performed for the value of *XRCC1* genetic polymorphism on the efficacy of chemotherapy and overall survival of prognosis. The results demonstrated that the patients with GG genotype were more sensitive to chemotherapy and had higher survival capacity. Interestingly, cancer patients are commonly resistant to chemotherapy, and this resistance has been lined with enhanced NER in cancer tissues, and most chemotherapy drugs will lead to the recognition and activation of the apoptotic program in DNA damage identification of molecular as well as DNA repair process by forming platinum--DNA adducts, such as anticancer drugs of platinum agents.[@b24-ott-9-7019] Also, cancer cells may resist against the platinum-based chemotherapy if their DNA repair ability is increased to remove those DNA adducts due to the function of platinum agents. Therefore, we assumed that genetic polymorphism of *XRCC1* rs25487 reduced repair ability of DNA damage and promoted tumor growth and metastasis, thus affecting the sensitivity of tumor cells to chemotherapeutic drugs. Consistent with our study, Gurubhagavatula et al[@b25-ott-9-7019] reported that *XRCC1* (Arg399Gln) DNA repair gene may act as an important prognostic factor in patients with advanced lung cancer.

More importantly, we found that the risk of endometrial carcinoma in the patients with the AA + GA genotype was increased when compared to GG genotype in *ERCC1* rs11615. ERCC1 protein XPF and ERCC4 can recognize damaged DNA 5′-end and function as 5′--3′ endonuclease of nucleic acids, thereby reducing the possibility of structural chromosome aberrations and guarantying genomic instability.[@b26-ott-9-7019] Recently, an epidemiological study suggested that inhibition of expression of *ERCC1* played an essential role in reducing the ability of DDP--DNA adduct repair, after which the tumor incidence increased with low resistance in drugs.[@b27-ott-9-7019] Furthermore, Ma et al[@b28-ott-9-7019] reported that the *ERCC1* rs11615 polymorphism contributed to the clinical outcomes of patients with gastrointestinal cancer, such as gastric cancer and colorectal cancer who were treated by oxaliplatin-based chemotherapy. Therefore, we may assume that influence of the alteration of AA + GA genotype decreased the nuclear nucleotide repair ability. Therefore, the increased risk of occurrence of endometrial carcinoma was observed in the patients with AA + GA genotype of *ERCC1* rs11615. Also, continuous data were analyzed to investigate the relationship between the *ERCC1* rs11615 genetic polymorphisms and chemotherapy efficiency. The results demonstrated that the patients with GG genotype were more sensitive to chemotherapeutic drugs. Similarly, Viguier et al[@b29-ott-9-7019] showed that the expressions of ERCC1 protein were changed when *ERCC1* codon 118 C (rs11615) was transferred to T, reducing the ability of DNA repair and weakening the impact of *ERCC1* on DNA damage caused by platinum drugs. Besides, the data also indicated that the patients with *ERCC1* codon 118 T/T genotype were more sensitive to platinum-based chemotherapy than the patients with C/T and C/C genotype.[@b29-ott-9-7019],[@b30-ott-9-7019] All the results revealed that the patients with wild-type C/C were more sensitive to chemotherapeutic drugs than heterozygous C/T and mutant T/T in *ERCC1* 118. Thus, we may propose that wild-type GG of *ERCC1* rs11615 promoted the chemotherapeutic drugs to target the tumor cells and inhibited the replication and transcription of DNA, resulting in apoptosis of tumor cells.

Conclusion
==========

Our study elucidated that *ERCC1* rs11615 and *XRCC1* rs25487 but not *XPA* rs1800975 polymorphisms correlate with response to chemotherapy in endometrial carcinoma. Therefore, the related genetic polymorphisms of DNA damage repair have implicated the pathogenesis of endometrial carcinoma, thus providing a theoretical basis of individualized treatment for this disease. However, our results demonstrated that there was no significant difference between XPA genetic polymorphisms and the occurrence and platinum-based chemotherapy efficiency of endometrial carcinoma. Therefore, further studies, with larger sample size, including clinical staging and postoperative follow-up data of the selected cases, are required to obtain the results reflecting relevance of *XPA* genetic polymorphisms and endometrial carcinoma.
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![Electropherogram of PCR products.\
**Notes:** (**A**) The enzyme digestion electropherogram of *ERCC1* rs11615; (**B**) the enzyme digestion electropherogram of *XRCC1* rs25487; and (**C**) the enzyme digestion electropherogram of *XPA* rs1800975.\
**Abbreviation:** PCR, polymerase chain reaction.](ott-9-7019Fig1){#f1-ott-9-7019}

![Survival curves of patients with endometrial carcinoma with different genotypes of *ERCC1* rs11615, *XRCC1* rs25487, and *XPA* rs1800975 polymorphisms.\
**Notes:** (**A**) *ERCC1* rs11615 polymorphism; (**B**) *XRCC1* rs25487 polymorphism; and (**C**) *XPA* rs1800975 polymorphism.\
**Abbreviation:** Cum, cumulative.](ott-9-7019Fig2){#f2-ott-9-7019}

###### 

Primer sequences of *ERCC1* rs11615, *XRCC1* rs25487, and *XPA* rs1800975 polymorphisms

  Primer name                         Primer sequence (5′--3′)           Primer length (bp)
  ----------------------------------- ---------------------------------- --------------------
  *ERCC1* rs11615                     F: AGGACCACAGGACACGCAGA            20
  R: CATAGAACAGTCCAGAACAC             20                                 
  *XRCC1* rs25487                     F: CCCCAAGTACAGCCAGGTC             19
  R: TGTCCCGCTCCTCTCAGTAG             20                                 
  *XPA* rs1800975                     F: ACGTTGGATGTCCGCGGGTTGCTCTAAAG   29
  R: ACGTTGGATGAGCTGGGAGCTAGGTCCTCG   30                                 

**Abbreviations:** F, forward; R, reverse; bp, base pair.

###### 

Frequency distribution of *ERCC1* rs11615, *XRCC1* rs25487, and *XPA* rs1800975 polymorphisms

  SNP               Case group (n=108), n (%)   Control group (n=110), n (%)   *P*-value   OR      95% CI
  ----------------- --------------------------- ------------------------------ ----------- ------- ---------------
  *ERCC1* rs11615                                                                                  
   GG               61 (56.5)                   93 (84.6)                      Ref                 
   GA               39 (36.1)                   15 (13.6)                      \<0.001     3.964   2.013--7.805
   AA               8 (7.4)                     2 (1.8)                        0.012       6.098   1.252--29.700
   AA + GA          47 (43.5)                   17 (15.4)                      \<0.001     4.215   2.218--8.010
   G allele         161 (74.5)                  201 (91.4)                                         Ref
   A allele         55 (25.5)                   19 (8.6)                       0.006       1.907   1.194--3.048
  *XRCC1* rs25487                                                                                  
   GG               46 (42.6)                   65 (59.1)                      Ref                 
   GA               46 (42.6)                   36 (32.7)                      0.044       1.806   1.014--3.215
   AA               16 (14.8)                   9 (8.2)                        0.041       2.512   1.021--6.178
   AA + GA          62 (57.4)                   45 (40.9)                      0.015       1.947   1.136--3.336
   G allele         138 (63.9)                  166 (75.5)                                         Ref
   A allele         78 (36.1)                   54 (24.5)                      0.009       1.738   1.148--2.629
  *XPA* rs1800975                                                                                  
   AA               41 (38.0)                   35 (31.8)                      Ref                 
   GA               39 (36.1)                   45 (40.9)                      0.342       0.740   0.397--1.379
   GG               28 (25.9)                   30 (27.3)                      0.515       0.797   0.402--1.580
   AA + GA          67 (62.0)                   75 (68.2)                      0.341       0.763   0.436--1.333
   A allele         121 (56.0)                  115 (52.3)                     Ref                 
   G allele         95 (44.0)                   105 (47.7)                     0.433       0.860   0.590--1.254

**Abbreviations:** SNP, single nucleotide polymorphism; OR, odds ratio; Ref, reference; CI, confidence interval.

###### 

Correlations of clinical characteristics of endometrial carcinoma patients with *ERCC1* rs11615, *XRCC1* rs25487, and *XPA* rs1800975 polymorphisms

  Clinical characteristics              *ERCC1* rs11615   *P*-value    *XRCC1* rs25487   *P*-value    *XPA* rs1800975   *P*-value                             
  ------------------------------------- ----------------- ------------ ----------------- ------------ ----------------- ----------- ------------ ------------ -------
  Age (years), n (%)                                                   0.104                                            0.063                                 0.119
   \<45                                 15 (31.9)         9 (14.8)                       17 (27.4)    7 (15.2)                      17 (25.4)    7 (17.1)     
   45--60                               25 (53.2)         41 (67.2)                      32 (51.6)    34 (73.9)                     36 (53.7)    30 (73.2)    
   \>60                                 7 (14.9)          11 (18.0)                      13 (21.0)    5 (10.9)                      14 (20.9)    4 (9.7)      
  BMI, mean ± SD                        25.83±5.36        25.46±6.17   0.744             25.89±6.13   25.25±5.39        0.574       25.84±6.24   25.25±5.08   0.611
  Menopause, n (%)                                                     0.014                                            0.010                                 0.062
   Yes                                  23 (48.9)         44 (72.1)                      32 (51.6)    35 (76.1)                     37 (55.2)    30 (73.2)    
   No                                   24 (51.1)         17 (27.9)                      30 (48.4)    11 (23.9)                     30 (44.8)    11 (26.8)    
  Pathologic type, n (%)                                               0.725                                            0.795                                 0.186
   EC                                   39 (83.0)         49 (80.3)                      50 (80.7)    38 (82.6)                     52 (77.6)    36 (87.8)    
   Non-EC                               8 (17.0)          12 (19.7)                      12 (19.3)    8 (17.4)                      15 (22.4)    5 (12.2)     
  Muscular invasion, n (%)                                             0.006                                            0.035                                 0.253
   Invasion \<1/2                       31 (66.0)         24 (39.3)                      37 (59.7)    18 (39.1)                     37 (55.2)    18 (43.9)    
   Invasion ≥1/2                        16 (34.0)         37 (60.7)                      25 (40.3)    28 (60.9)                     30 (44.8)    23 (56.1)    
  Maximum lesion diameter (cm), n (%)                                  0.001                                            0.025                                 0.187
   1                                    7 (14.9)          22 (36.1)                      14 (22.6)    15 (32.6)                     18 (26.9)    11 (26.8)    
   1--2                                 17 (36.2)         28 (45.9)                      22 (35.5)    23 (50.0)                     24 (35.8)    21 (51.2)    
   \>2                                  23 (48.9)         11 (18.0)                      26 (41.9)    8 (17.4)                      25 (37.3)    9 (22.0)     
  Tumor stage, n (%)                                                   0.019                                            \<0.001                               0.123
   I stage                              12 (25.5)         32 (52.5)                      13 (21.0)    31 (67.4)                     25 (37.3)    19 (46.3)    
   II stage                             10 (21.3)         8 (13.1)                       10 (16.1)    8 (17.4)                      15 (22.4)    3 (7.4)      
   III stage                            25 (53.2)         21 (34.4)                      39 (62.9)    7 (15.2)                      27 (44.3)    19 (46.3)    
  Lymphatic metastasis, n (%)                                          \<0.001                                          0.024                                 0.762
   Present                              18 (38.3)         2 (3.3)                        16 (25.8)    4 (8.7)                       13 (19.4)    7 (17.1)     
   Absent                               29 (61.7)         59 (96.7)                      46 (74.2)    42 (91.3)                     54 (80.6)    34 (82.9)    

**Abbreviations:** BMI, body mass index; EC, endometrioid carcinoma.

###### 

Correlations of chemotherapy efficacy of endometrial carcinoma patients with *ERCC1* rs11615, *XRCC1* rs25487, and *XPA* rs1800975 polymorphisms

  -----------------------------------------------------------------------------------------------------
  SNP               Genotype    Response\   Nonresponse\   *χ*^2^   *P*-value   OR             95% CI
                                (n, %)      (n, %)                                             
  ----------------- ----------- ----------- -------------- -------- ----------- -------------- --------
  *ERCC1* rs11615   GA + AA     17 (36.2)   30 (63.8)      5.544    0.019       0.394          Ref

  GG                36 (59.0)   25 (41.0)                                       0.180--0.862   

  *XRCC1* rs25487   GA + AA     21 (33.9)   41 (66.1)      13.460   \<0.001     0.224          Ref

  GG                32 (69.6)   14 (30.4)                                       0.099--0.509   

  *XPA* rs1800975   GA + GG     30 (44.8)   37 (55.2)      1.305    0.253       0.635          Ref

  AA                23 (56.1)   18 (43.9)                                       0.290--1.388   
  -----------------------------------------------------------------------------------------------------

**Abbreviations:** CI, confidence interval; SNP, single nucleotide polymorphism; OR, odds ratio; Ref, reference.

###### 

Correlations of toxic effects in endometrial carcinoma patients with *ERCC1* rs11615, *XRCC1* rs25487, and *XPA* rs1800975 polymorphisms

  SNP                      Digestive system   Hematological system   Liver/kidney toxicity   Nervous system                                       
  ------------------------ ------------------ ---------------------- ----------------------- ---------------- ----------- ----------- ----------- -----------
  *ERCC1* rs11615, n (%)                                                                                                                          
   GG                      19 (31.1)          21 (34.4)              20 (32.8)               21 (34.4)        26 (42.6)   12 (19.7)   10 (16.4)   17 (27.9)
   GA + AA                 16 (34.0)          16 (34.0)              17 (36.2)               12 (25.5)        11 (23.4)   22 (46.8)   16 (34.0)   6 (12.8)
   *χ*^2^                  0.044                                     0.660                                    8.713                   6.200       
   *P*-value               0.833                                     0.417                                    0.003                   0.013       
  *XRCC1* rs25487, n (%)                                                                                                                          
   GG                      16 (34.8)          15 (32.6)              19 (41.3)               16 (34.8)        20 (43.5)   10 (21.7)   9 (19.6)    15 (32.6)
   GA + AA                 19 (30.7)          22 (35.5)              18 (29.0)               17 (27.4)        17 (27.4)   24 (38.7)   17 (27.4)   8 (12.9)
   *χ*^2^                  0.196                                     0.057                                    4.410                   4.573       
   *P*-value               0.658                                     0.811                                    0.036                   0.033       
  *XPA* rs1800975, n (%)                                                                                                                          
   AA                      13 (31.7)          14 (34.2)              13 (31.7)               13 (31.7)        17 (41.5)   14 (34.2)   12 (29.3)   8 (19.5)
   GA + GG                 22 (32.8)          23 (34.3)              24 (35.8)               20 (29.9)        20 (29.9)   20 (29.9)   14 (20.9)   15 (22.4)
   *χ*^2^                  0.004                                     0.136                                    0.164                   0.653       
   *P*-value               0.952                                     0.713                                    0.686                   0.419       

**Abbreviation:** SNP, single nucleotide polymorphism.

###### 

Cox regression analysis

  Variables                     B        SE      Wald    Sig     Exp (*B*)   95% CI for Exp (B)   
  ----------------------------- -------- ------- ------- ------- ----------- -------------------- -------
  *ERCC1* rs11615 GG            −0.872   0.398   4.795   0.029   0.418       0.192                0.913
  *XRCC1* rs25487 GG            −1.546   0.644   5.762   0.016   0.213       0.06                 0.753
  Muscular invasion             −0.177   0.382   0.215   0.643   0.838       0.396                1.771
  Tumor stage (I + II stages)   −1.104   0.472   5.473   0.019   0.331       0.131                0.836

**Abbreviations:** SE, standard error; Sig, significance; Exp, exponential.
